USFDA Compliance & Regulatory Risk
The single largest revenue risk for exporters. A facility-aware risk lens across the universe — observations, risk scores and Rubicon's own inspection posture.
Tracks the biggest non-market risk for pharma exporters: US FDA factory inspections. A bad outcome at a key plant can freeze a company's approvals and shipments overnight.
The heatmap ranks companies by a composite risk score (redder = higher risk), blending observation counts, how concentrated their factories are, and US exposure. Below it is Rubicon's own inspection timeline.
- Form 483
- — The list of problems an FDA inspector writes up at the end of a factory inspection.
- NAI / VAI / OAI
- — Inspection outcomes: No Action / Voluntary Action / Official Action (worst). OAI ≈ warning letter.
- Warning letter
- — A formal FDA escalation that can block new product approvals from that site.
- Import alert
- — FDA can detain a factory's products at the US border — directly hits revenue.
Regulatory Risk Heatmap
Risk score (higher = worse) blends observations, facility concentration & remediation history
| Company | Segment | Facilities | FDA observations | US revenue % | Risk score |
|---|---|---|---|---|---|
| Lupin | Diversified | 15 | 5 | 36% | 45 |
| Aurobindo Pharma | US Generics | 13 | 6 | 47% | 44 |
| Biocon | Biosimilars | 12 | 3 | 0% | 44 |
| Cipla | Diversified | 22 | 5 | 28% | 43 |
| Sun Pharmaceutical Industries | Diversified | 40 | 6 | 31% | 42 |
| Alembic Pharmaceuticals | US Generics | 8 | 4 | 28% | 42 |
| Zydus Lifesciences | Diversified | 30 | 4 | 47% | 40 |
| Piramal Pharma | CDMO/CRDMO | 17 | 0 | 0% | 40 |
| Granules India | API | 10 | 4 | 79% | 40 |
| Dr. Reddy's Laboratories | Diversified | 23 | 4 | 45% | 38 |
| Alkem Laboratories | Domestic Formulations | 18 | 4 | 25% | 38 |
| Rubicon Research | Complex Generics | 3 | 3 | 72% | 36 |
| Laurus Labs | API | 14 | 1 | 0% | 35 |
| Torrent Pharmaceuticals | Domestic Formulations | 9 | 3 | 10% | 30 |
| Neuland Laboratories | CDMO/CRDMO | 3 | 0 | 0% | 30 |
| Caplin Point Laboratories | US Generics | 6 | 1 | 21% | 30 |
| Divi's Laboratories | API | 3 | 1 | 0% | 28 |
| Suven Pharmaceuticals (now Cohance Lifesciences) | CDMO/CRDMO | 11 | 0 | 0% | 28 |
| Ajanta Pharma | Domestic Formulations | 7 | 1 | 23% | 28 |
| Syngene International | CDMO/CRDMO | 4 | 5 | 0% | 26 |
| Eris Lifesciences | Domestic Formulations | 5 | 0 | 0% | 26 |
| J.B. Chemicals & Pharmaceuticals | Domestic Formulations | 6 | 0 | 0% | 24 |
| Mankind Pharma | Domestic Formulations | 30 | 0 | 0% | 22 |
| Pfizer (India) | Domestic Formulations | 1 | 0 | 0% | 18 |
| GSK Pharmaceuticals (India) | Domestic Formulations | 2 | 0 | 0% | 16 |
| Abbott India | Domestic Formulations | 1 | 0 | 0% | 16 |
Rubicon — Facility Inspection Timeline
Detailed regulatory event history for the focus company
Ambernath has shipped to the US since 2015 and cleared multiple USFDA inspections. Per company disclosures, its US-facing sites have NAI/VAI classifications with no Official Action Indicated (OAI) on record. (Specific 483 detail is modeled.)
Satara is a USFDA-inspected manufacturing site supporting the US/regulated-market portfolio.
Formulations facility acquired from Alkem Laboratories in Jun-2025 to expand capacity for the US/regulated pipeline.
Canadian formulation-development R&D center (acquired 2020) complementing the Thane (Mumbai) R&D HQ.